Signaling pathway-focused gene expression profiling in pressure overloaded hearts

Annali dell'Istituto Superiore di Sanita

Volumn 47, Issue 3, 2011, Pages 290-295

  Musumeci, Marco ^a   Maccari, Sonia ^a   Corritore, Elisa ^a   Massimi, Alessia ^a   Stati, Tonino ^a   Marano, Giuseppe ^a   Catalano, Liviana ^b  

^a Dipartimento del Farmaco   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

blockers; Gene expression; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL; RNA;

ANIMAL; AORTA; AORTA VALVE STENOSIS; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CARDIOMEGALY; DRUG EFFECT; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; HEART; HEMODYNAMICS; ISOLATION AND PURIFICATION; MALE; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; PRESSURE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA; AORTIC VALVE STENOSIS; CARDIOMEGALY; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; HEART; HEMODYNAMICS; MALE; MICE; MICE, INBRED C57BL; PRESSURE; PROPRANOLOL; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 80053521351     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: 10.4415/ANN-11-03-09     Document Type: Article

References (21)

1. 1-adrenergic receptor transgenic mice. PNAS 1999;96:7059-64. (Pubitemid 29275009)
2. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000;101:1707-14. (Pubitemid 30196632)
3. Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP, Kudej RK, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsa overexpression. Circ Res 1996;78:517-24.
4. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ Res 2001;89:997-1004. (Pubitemid 34640866)
5. Rapacciuolo A, Esposito G, Caron K, Mao L, Thomas SA, Rockman HA. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol 2001;38:876-82. (Pubitemid 32835767)
6. Ostman-Smith I. Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat. Br J Pharmacol 1995;116:2703-9.
7. Marano G, Palazzesi S, Fadda A, Vergari A, Ferrari AU. Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of β-adrenoceptor blockade. J Hypertens 2002;20:763-9. (Pubitemid 34913722)
8. Patrizio M, Musumeci M, Stati T, Fasanaro P, Palazzesi S, Catalano L, Marano G. Propranolol causes a paradoxical enhancement of cardiomyocyte foetal gene response to hypertrophic stimuli. Br J Pharmacol 2007;152:216-22. (Pubitemid 47517602)
9. Asai K, Yang GP, Geng YJ, Takagi G, Bishop S, Ishikawa Y, et al. β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse. J Clin Invest 1999;104:551-8.
10. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. PNAS 1991;88:8277-81. (Pubitemid 21915339)
11. Marano G, Vergari A, Catalano L, Gaudi S, Palazzesi S, Musumeci M, et al. Na/H exchange inhibition attenuates left ventricular remodeling and preserves systolic function in pressure- overloaded hearts. Br J Pharmacol 2004;141:526-32. (Pubitemid 38297015)
12. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3:1101-8. (Pubitemid 351818697)
13. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006;25:5854-63. (Pubitemid 44453441)
14. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602. (Pubitemid 27152402)
15. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7. (Pubitemid 33679835)
16. Hinrichsen R, Hansen AH, Haunso S, Busk PK. phosphorylation of pRb by cyclin D kinase is necessary for development of cardiac hypertrophy. Cell Prolif 2008;41:813-29.
17. Li JM, Poolman RA, Brooks G. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol 1998;275:H814-22.
18. Li JM, Brooks G. Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy. Am J Physiol 1997;273:H1358-67.
19. Nozato T, Ito H, Watanabe M, Ono Y, Adachi S, Tanaka H, et al. Overexpression of cdk Inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy. J Mol Cell Cardiol 2001;33:1493-504.
20. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signaling in fibroblasts. Nature 2008; 456:980-4.
21. Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, et al. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 2005;46:1213-8. (Pubitemid 41533028)